Evaluation of mental health and the use of antidepressants and anxiolytics in young adults during the COVID-19 pandemic in Brazil

Detalhes bibliográficos
Autor(a) principal: Melo, Cauane da Silva
Data de Publicação: 2022
Outros Autores: Wirowski, Natália, Oliveira, Marlon Pereira de, Vieira, Igor Soares, Moreira, Fernanda Pedrotti
Tipo de documento: Artigo
Idioma: por
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/30095
Resumo: The objective of the study was to assess the prevalence of anxious, depressive and stress symptoms, as well as the consumption of antidepressants and anxiolytics among young adults during the COVID-19 pandemic in Brazil. This is a cross-sectional study conducted online via social media involving individuals between 18 and 35 years old. Participants answered a sociodemographic questionnaire and were asked about the use of anxiolytics and antidepressants. Mental health was assessed using the DASS-21 scale. The sample was composed of 349 participants of both sexes, and 71 (20.3%) used antidepressants and/or anxiolytics during the pandemic. Of these, 20.5% used anxiolytics, 31.8% used antidepressants, and 28.4% used both concomitantly. The main anxiolytic drug reported was clonazepam, and the antidepressant, fluoxetine. About mental health, a prevalence of 27.5% anxious symptoms, 31.8% depressive symptoms, and 30.7% stress symptoms was found. The results also show that the prevalence of depressive symptoms and stress reached 51.3% and 50.0%, respectively, in the participants who, prior to the pandemic, were already using medication for depression control, while in the participants who reported taking medication for anxiety control prior to the pandemic, the prevalence of anxious symptoms was 61.0%, depressive 56.4%, and stress 57.1%. Thus, high prevalence of mental disorders and use of medications were found, and such findings serve as an alert for the development of specific interventions.
id UNIFEI_e26c8ee11a0a7d253ea716d632c2ac6b
oai_identifier_str oai:ojs.pkp.sfu.ca:article/30095
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Evaluation of mental health and the use of antidepressants and anxiolytics in young adults during the COVID-19 pandemic in BrazilEvaluación de la salud mental y del uso de antidepressivos y ansiolíticos em adultos jóvenes durante la pandemia de COVID-19 en BrasilAvaliação da saúde mental e do consumo de antidepressivos e ansiolíticos em adultos jovens durante a pandemia da COVID-19 no BrasilCOVID-19PandemiaSalud mentalAntidepresivosAnsiolíticosEnseñanza en salud.COVID-19PandemiaSaúde MentalAntidepressivosAnsiolíticosEnsino em saúde.COVID-19PandemicMental healthAntidepressantsAnxiolyticsHealth teaching.The objective of the study was to assess the prevalence of anxious, depressive and stress symptoms, as well as the consumption of antidepressants and anxiolytics among young adults during the COVID-19 pandemic in Brazil. This is a cross-sectional study conducted online via social media involving individuals between 18 and 35 years old. Participants answered a sociodemographic questionnaire and were asked about the use of anxiolytics and antidepressants. Mental health was assessed using the DASS-21 scale. The sample was composed of 349 participants of both sexes, and 71 (20.3%) used antidepressants and/or anxiolytics during the pandemic. Of these, 20.5% used anxiolytics, 31.8% used antidepressants, and 28.4% used both concomitantly. The main anxiolytic drug reported was clonazepam, and the antidepressant, fluoxetine. About mental health, a prevalence of 27.5% anxious symptoms, 31.8% depressive symptoms, and 30.7% stress symptoms was found. The results also show that the prevalence of depressive symptoms and stress reached 51.3% and 50.0%, respectively, in the participants who, prior to the pandemic, were already using medication for depression control, while in the participants who reported taking medication for anxiety control prior to the pandemic, the prevalence of anxious symptoms was 61.0%, depressive 56.4%, and stress 57.1%. Thus, high prevalence of mental disorders and use of medications were found, and such findings serve as an alert for the development of specific interventions.El objetivo del estudio fue evaluar la prevalencia de síntomas de ansiedad, depresión y estrés, así como el consumo de antidepresivos y ansiolíticos entre adultos jóvenes durante la pandemia de COVID-19 en Brasil. Se trata de un estudio transversal realizado online a través de redes sociales en el que participaron personas entre 18 y 35 años. Los participantes respondieron un cuestionario sociodemográfico y se preguntó sobre el uso de ansiolíticos y antidepresivos. La salud mental se evaluó mediante la escala DASS-21. La muestra estuvo compuesta por 349 participantes de ambos sexos, de los cuales 71 (20,3%) utilizaron antidepresivos y/o ansiolíticos durante la pandemia. De estos, el 20,5% utilizaba ansiolíticos, el 31,8% antidepresivos y el 28,4% ambos de forma concomitante. El principal fármaco ansiolítico informado fue el clonazepam y el antidepresivo fluoxetina. Cuanto la salud mental, se encontró una prevalencia de 27,5% de síntomas ansiosos, 31,8% de depresión y 30,7% de estrés. Los resultados también muestran que la prevalencia de síntomas depresivos y de estrés alcanzó el 51,3 % y el 50,0 %, respectivamente, en los participantes que usaban medicamentos para el control de la depresión antes de la pandemia, mientras que en los participantes que reportaron consumir medicamentos para el control de la ansiedad, antes de la pandemia, la prevalencia de síntomas ansiosos era del 61,0%, depresivos del 56,4% y de estrés del 57,1%. Así, se encontraron altas prevalencias de trastornos mentales, así como el uso de medicamentos, sirviendo de alerta para el desarrollo de intervenciones específicas.O objetivo do estudo foi avaliar a prevalência de sintomas ansiosos, depressivos e de estresse, bem como o consumo de antidepressivos e ansiolíticos entre adultos jovens durante a pandemia da COVID-19 no Brasil. Trata-se de um estudo transversal realizado online pelas redes sociais envolvendo indivíduos entre 18 e 35 anos. Os participantes responderam um questionário sociodemográfico e foram indagados sobre o uso de ansiolíticos e antidepressivos. A saúde mental foi avaliada através da escala DASS-21. A amostra foi composta por 349 participantes de ambos os sexos, sendo que 71 (20,3%) fizeram uso de antidepressivos e/ou ansiolíticos durante a pandemia. Destes, 20,5% faziam uso de ansiolíticos, 31,8% antidepressivos e 28,4% de ambos concomitantemente. O principal medicamento ansiolítico relatado foi o clonazepam, e o antidepressivo, a fluoxetina. Sobre a saúde mental, foi encontrada uma prevalência de 27,5% de sintomas ansiosos, 31,8% depressivos e 30,7% de estresse. Os resultados também mostram que as prevalências de sintomas depressivos e de estresse chegaram a 51,3% e 50,0%, respectivamente nos participantes que anteriormente à pandemia já faziam uso de medicamentos para controle da depressão, já nos participantes que relataram consumir medicamentos para o controle de ansiedade, anterior a pandemia, a prevalência de sintomas ansiosos foi de 61,0%, depressivos 56,4% e de estresse 57,1%. Assim, foram encontradas elevadas prevalências de transtornos mentais bem como o uso de medicamentos, servindo tais achados de alerta para o desenvolvimento de intervenções específicas.Research, Society and Development2022-05-29info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/3009510.33448/rsd-v11i7.30095Research, Society and Development; Vol. 11 No. 7; e40511730095Research, Society and Development; Vol. 11 Núm. 7; e40511730095Research, Society and Development; v. 11 n. 7; e405117300952525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/30095/25996Copyright (c) 2022 Cauane da Silva Melo; Natália Wirowski; Marlon Pereira de Oliveira; Igor Soares Vieira; Fernanda Pedrotti Moreirahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessMelo, Cauane da Silva Wirowski, Natália Oliveira, Marlon Pereira de Vieira, Igor Soares Moreira, Fernanda Pedrotti 2022-06-06T15:12:05Zoai:ojs.pkp.sfu.ca:article/30095Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:46:58.643324Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Evaluation of mental health and the use of antidepressants and anxiolytics in young adults during the COVID-19 pandemic in Brazil
Evaluación de la salud mental y del uso de antidepressivos y ansiolíticos em adultos jóvenes durante la pandemia de COVID-19 en Brasil
Avaliação da saúde mental e do consumo de antidepressivos e ansiolíticos em adultos jovens durante a pandemia da COVID-19 no Brasil
title Evaluation of mental health and the use of antidepressants and anxiolytics in young adults during the COVID-19 pandemic in Brazil
spellingShingle Evaluation of mental health and the use of antidepressants and anxiolytics in young adults during the COVID-19 pandemic in Brazil
Melo, Cauane da Silva
COVID-19
Pandemia
Salud mental
Antidepresivos
Ansiolíticos
Enseñanza en salud.
COVID-19
Pandemia
Saúde Mental
Antidepressivos
Ansiolíticos
Ensino em saúde.
COVID-19
Pandemic
Mental health
Antidepressants
Anxiolytics
Health teaching.
title_short Evaluation of mental health and the use of antidepressants and anxiolytics in young adults during the COVID-19 pandemic in Brazil
title_full Evaluation of mental health and the use of antidepressants and anxiolytics in young adults during the COVID-19 pandemic in Brazil
title_fullStr Evaluation of mental health and the use of antidepressants and anxiolytics in young adults during the COVID-19 pandemic in Brazil
title_full_unstemmed Evaluation of mental health and the use of antidepressants and anxiolytics in young adults during the COVID-19 pandemic in Brazil
title_sort Evaluation of mental health and the use of antidepressants and anxiolytics in young adults during the COVID-19 pandemic in Brazil
author Melo, Cauane da Silva
author_facet Melo, Cauane da Silva
Wirowski, Natália
Oliveira, Marlon Pereira de
Vieira, Igor Soares
Moreira, Fernanda Pedrotti
author_role author
author2 Wirowski, Natália
Oliveira, Marlon Pereira de
Vieira, Igor Soares
Moreira, Fernanda Pedrotti
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Melo, Cauane da Silva
Wirowski, Natália
Oliveira, Marlon Pereira de
Vieira, Igor Soares
Moreira, Fernanda Pedrotti
dc.subject.por.fl_str_mv COVID-19
Pandemia
Salud mental
Antidepresivos
Ansiolíticos
Enseñanza en salud.
COVID-19
Pandemia
Saúde Mental
Antidepressivos
Ansiolíticos
Ensino em saúde.
COVID-19
Pandemic
Mental health
Antidepressants
Anxiolytics
Health teaching.
topic COVID-19
Pandemia
Salud mental
Antidepresivos
Ansiolíticos
Enseñanza en salud.
COVID-19
Pandemia
Saúde Mental
Antidepressivos
Ansiolíticos
Ensino em saúde.
COVID-19
Pandemic
Mental health
Antidepressants
Anxiolytics
Health teaching.
description The objective of the study was to assess the prevalence of anxious, depressive and stress symptoms, as well as the consumption of antidepressants and anxiolytics among young adults during the COVID-19 pandemic in Brazil. This is a cross-sectional study conducted online via social media involving individuals between 18 and 35 years old. Participants answered a sociodemographic questionnaire and were asked about the use of anxiolytics and antidepressants. Mental health was assessed using the DASS-21 scale. The sample was composed of 349 participants of both sexes, and 71 (20.3%) used antidepressants and/or anxiolytics during the pandemic. Of these, 20.5% used anxiolytics, 31.8% used antidepressants, and 28.4% used both concomitantly. The main anxiolytic drug reported was clonazepam, and the antidepressant, fluoxetine. About mental health, a prevalence of 27.5% anxious symptoms, 31.8% depressive symptoms, and 30.7% stress symptoms was found. The results also show that the prevalence of depressive symptoms and stress reached 51.3% and 50.0%, respectively, in the participants who, prior to the pandemic, were already using medication for depression control, while in the participants who reported taking medication for anxiety control prior to the pandemic, the prevalence of anxious symptoms was 61.0%, depressive 56.4%, and stress 57.1%. Thus, high prevalence of mental disorders and use of medications were found, and such findings serve as an alert for the development of specific interventions.
publishDate 2022
dc.date.none.fl_str_mv 2022-05-29
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/30095
10.33448/rsd-v11i7.30095
url https://rsdjournal.org/index.php/rsd/article/view/30095
identifier_str_mv 10.33448/rsd-v11i7.30095
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/30095/25996
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 11 No. 7; e40511730095
Research, Society and Development; Vol. 11 Núm. 7; e40511730095
Research, Society and Development; v. 11 n. 7; e40511730095
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052795548860416